APGE241115P85000
- 0.00
- 0.000.00%
Apogee Therapeutics Newsroom
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush
Apogee Therapeutics Analyst Ratings
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $81
Buy Rating on Apogee Therapeutics' APG808: Market Potential and Treatment Advantages Amid FDA Approval Landscape
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
Apogee Therapeutics, Inc. (APGE) Receives a Buy From TD Cowen
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics Analyst Ratings
Buy Rating Affirmed for Apogee Therapeutics as APG777 Shows Promise and Pipeline Progresses
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE)
Buy Rating Endorsed for Apogee Therapeutics Amid Promising APG777 Phase 1 Results
Apogee Therapeutics Analyst Ratings
Stifel Nicolaus Sticks to Its Buy Rating for Apogee Therapeutics, Inc. (APGE)
Stifel Nicolaus Keeps Their Buy Rating on Apogee Therapeutics, Inc. (APGE)
Guggenheim Maintains Buy on Apogee Therapeutics, Raises Price Target to $44
Apogee Therapeutics Analyst Ratings